ANTIMICROBIAL THERAPY OF PATIENTS WITH FAN-ASSOCIATED PNEUMONIA: FOCUS ON DOPIRENEM

Abstract

The fan-associated pneumonia currently is a leading reason of mortality of patients in resuscitation and intensive care unit. Development of the disease is accompanied by serious clinical and economic consequences. The adequate antibacterial therapy plays the determining role in the favorable outcome in pneumonia. Doripemen is a new parenteral 1-beta-methyl-carbapenem that was launched into the pharmaceutical market of Russia in 2008.The purpose of this review is to generalize the results accumulated to this moment on effectiveness of doripenem in therapy of fan-associated pneumonia.

Keywords

• doripenem
• carbapenem
• fap
• alv
• resuscitation and intensive care unit
• antibiotic resistance